{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decitabine+and+Cedazuridine", "query": { "intervention": "Decitabine and Cedazuridine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decitabine+and+Cedazuridine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T18:54:34.426Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04953910", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2022-12-23", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04953910" }, { "nct_id": "NCT04817241", "title": "Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2022-02-10", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 7, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Buffalo", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04817241" }, { "nct_id": "NCT07148947", "title": "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2026-03-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148947" }, { "nct_id": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2025-05-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 133, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 113 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672146" }, { "nct_id": "NCT05673200", "title": "Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-09-25", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05673200" }, { "nct_id": "NCT05037500", "title": "Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2022-01-26", "completion_date": "2025-01-03", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05037500" }, { "nct_id": "NCT06284460", "title": "Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pathway Mutant Myelodysplastic Syndromes", "Myelodysplastic Neoplasm", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "ASTX029", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-01-31", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06284460" }, { "nct_id": "NCT07437950", "title": "Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 126, "start_date": "2027-04-18", "completion_date": "2034-09-22", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 26, "location_summary": "Bloomington, Illinois • Canton, Illinois • Carthage, Illinois + 20 more", "locations": [ { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" }, { "city": "Carthage", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07437950" }, { "nct_id": "NCT04975919", "title": "Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Biphenotypic Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-09-29", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975919" }, { "nct_id": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma (RRMM)", "Metastatic Colorectal Cancer (mCRC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Higher-Risk Myelodysplastic Syndrome (HR-MDS)", "Acute Myeloid Leukemia (AML)", "Newly Diagnosed Intermediate/High-Risk MDS" ], "interventions": [ { "name": "KPT-8602", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2016-01", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-09-01T18:54:34.426Z", "location_count": 26, "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649790" } ] }